TOP TEN perturbations for 39042_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39042_at
Selected probe(set): 203673_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39042_at (203673_at) across 6674 perturbations tested by GENEVESTIGATOR:
HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Relative Expression (log2-ratio):-3.2454967Number of Samples:3 / 3
| Experimental | HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) |
| Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C. | |
| Control | HIF-1a/HIF-2a depletion study 1 (normoxia; AB81) |
| Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. |
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (adenocarcinoma, NOS; metastatic)
Relative Expression (log2-ratio):2.0979939Number of Samples:2 / 7
| Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
| Control | expO ovary cancer study 1 (adenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary adenocarcinoma (NOS) of the ovary. |
atopic dermatitis study 21 (lesional; whole skin) / atopic dermatitis study 21 (non-lesional; whole skin)
Relative Expression (log2-ratio):-1.9097157Number of Samples:5 / 5
| Experimental | atopic dermatitis study 21 (lesional; whole skin) |
| Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | atopic dermatitis study 21 (non-lesional; whole skin) |
| Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. |
expO ovary cancer study 1 (papillary serous cystadenocarcinoma; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Relative Expression (log2-ratio):-1.8623676Number of Samples:51 / 2
| Experimental | expO ovary cancer study 1 (papillary serous cystadenocarcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the ovary. | |
| Control | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. |
dexamethasone study 9 (24h) / EtOH treated CCRF-CEM-C7H2 cell sample
Relative Expression (log2-ratio):1.7708826Number of Samples:3 / 3
| Experimental | dexamethasone study 9 (24h) |
| CCRF-CEM-C7H2 cells cultured in the presence of dexamethansone (10e-7M) for 24 hours. ATC code:, , , , , , , , , , | |
| Control | EtOH treated CCRF-CEM-C7H2 cell sample |
| CCRF-CEM-C7H2 cells treated for 24 hours with 0.1% ethanol (EtOH) as carrier control. |
diphenylcyclopropenone study 1 (early) / placebo treated skin tissue
Relative Expression (log2-ratio):-1.711175Number of Samples:10 / 11
| Experimental | diphenylcyclopropenone study 1 (early) |
| Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:--- | |
| Control | placebo treated skin tissue |
| Skin biopsy samples of healthy volunteers exposed to placebo for 3 days. |
diphenylcyclopropenone study 1 (late) / diphenylcyclopropenone study 1 (early)
Relative Expression (log2-ratio):1.654355Number of Samples:6 / 10
| Experimental | diphenylcyclopropenone study 1 (late) |
| Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 4 to 8 months. ATC code:--- | |
| Control | diphenylcyclopropenone study 1 (early) |
| Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:--- |
clonidine study 5 (1615 uM; hES-Heps) / vehicle (DMSO) treated hES-Heps cell sample
Relative Expression (log2-ratio):1.626585Number of Samples:3 / 8
| Experimental | clonidine study 5 (1615 uM; hES-Heps) |
| hES-Heps cells exposed to 1615 uM clonidine (dissolved in 0.5% v/v DMSO) for 72 hours. Chemical was added at day 22 of differentiation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:, , , , | |
| Control | vehicle (DMSO) treated hES-Heps cell sample |
| hES-Heps cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Vehicle was added at day 22 of differentiation. |
HIF-1a depletion study 2 (normoxia; AB81) / control AB81 cell sample (normoxia)
Relative Expression (log2-ratio):1.6183786Number of Samples:3 / 3
| Experimental | HIF-1a depletion study 2 (normoxia; AB81) |
| Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a (Hypoxia-inducible factor 1-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. | |
| Control | control AB81 cell sample (normoxia) |
| Human podocyte cell line AB81 treated with normoxia (20% O2) for 24 hours. Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. |
atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):1.5621815Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (non-lesional; whole skin) |
| Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |